CD8A and cancer: In a pan-cancer analysis (N = 2,023; 632 deaths), we observed that patients had longer OS with high intratumoral CD8+, PD-1+, CD8+PD-1+, or FOXP3+ cell counts compared with those with intermediate or low cell counts (all log-rank P < .0001, Fig 2A).